世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

膀胱がん治療薬の市場調査:化学療法が主要な薬物タイプであり続ける


Market Study on Bladder Cancer Treatment Drugs: Chemotherapy to Remain Leading Drug Type

膀胱がん治療薬市場-レポートスコープ Persistence Market Research社の調査レポート「世界の膀胱癌治療薬市場」は、機会や現在の市場環境を評価し、市場に影響を与える対応セクションに関する詳細な分析と最... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Persistence Market Research
パーシスタンスマーケットリサーチ
2023年3月24日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
394 英語

 

サマリー

膀胱がん治療薬市場-レポートスコープ

Persistence Market Research社の調査レポート「世界の膀胱癌治療薬市場」は、機会や現在の市場環境を評価し、市場に影響を与える対応セクションに関する詳細な分析と最新情報を提供します。この調査は、市場の促進要因、抑制要因、動向、機会を含む現在の市場力学に関する詳細な洞察を提供します。この市場調査の主な目的は、2023年から2033年の予測期間中に市場がどのように推移するかについての独占情報を提示することです。

市場の成功的な成長のための重要な指標は、市場の前年比(YoY)成長分析、複合年間成長率(CAGR)を含むこの包括的なレポートで提示され、Persistence Market Research社の調査で網羅的に説明されています。この調査研究は、読者が膀胱癌治療薬の需要と調査期間中の定量的な開発機会を知るためのサポートとなります。

この調査は、投資家、メーカー、サービスプロバイダー、流通業者、サプライヤーなどの景観の株主にとって有益であり、膀胱癌治療薬市場で繁栄するために適切なビジネス戦略を開発するのに役立ちます。このPersistence Market Researchの調査で示された洞察と情報は、膀胱癌治療薬市場の株主、業界専門家、投資家、研究者、記者だけでなく、ビジネス愛好家も活用することができます。

市場統計、ならびに膀胱癌治療薬市場のビジネスシナリオに影響を与えるマクロ経済変数だけでなくマクロ経済変数に関連する情報も、現在の研究に含まれています。市場の潜在的な発展に応じて、実質的な洞察も本レポートに記載されています。さらに、本レポートで提出されたデータにより、業界のマイナーな企業や新規参入者は、市場で牽引力を発揮するために適切な企業選択をする際に役立つことができます。

主要な市場セグメント

Persistence Market Research社の膀胱癌治療薬市場に関する調査レポートは、癌の種類、癌のグレード、薬剤の種類、流通チャネル、地域という5つの重要なセグメントに分けられた情報を提供しています。本レポートでは、これらのカテゴリーに関連する重要な市場力学と成長パラメータに関する包括的なデータと情報を提供します。

癌の種類

非筋肉浸潤性膀胱がん
筋層浸潤性膀胱がん
がんの悪性度

低悪性度膀胱がん
高悪性度膀胱がん
薬剤の種類

免疫療法
カルメット・ゲラン菌
アベルマブ
ニボルマブ
ペムブロリズマブ
その他
化学療法
マイトマイシンC
ドセタキセル
パクリタキセル
シスプラチン
その他
標的治療薬
エルダフィチニブ
エンフルトゥマブ・ベドチン-ejfv
サシツズマブ・ゴビテカン
その他
販売チャネル

病院薬局
小売薬局
スペシャリティファーマシー
オンライン薬局
地域別

北アメリカ
中南米
ヨーロッパ
南アジア
東アジア
オセアニア
中東・アフリカ
本調査で回答した主な質問

今後数年間、膀胱がん治療薬メーカーにとって最も収益性の高い市場であり続けるのはどの地域か?
トレンドの変化は市場にどのような影響を与えるか?
COVID-19の危機は市場成長にどのような影響を与えたか?
市場関係者はどのようにして先進地域の低空飛行の機会を捉えることができるのか?
市場関係者は、このランドスケープにおける自らのポジションを形成するために、どのような戦略を持っているのか?
投資家が市場に投資する際に認識する必要があり、取り組む可能性のある抑制要因とは?
市場に影響を与える発展的なトレンドは何ですか?
膀胱がん治療薬市場の企業は、先進国および新興国での成長機会をどのように利用できるのか?
調査方法

Persistence Market Research社の調査レポートでは、膀胱癌治療薬市場の成長に関する広範な調査を実施し、市場の将来の成長パラメータに関する結論を得るために、独自の調査手法を利用しています。この調査手法は、一次調査と二次調査を組み合わせたもので、アナリストが結論の正確性と信頼性を確保するのに役立ちます。

市場調査作成時にアナリストが参照した二次資料には、政府機関の統計、業界誌、白書、社内外の独自データベースなどがあります。アナリストは、一次資料として、本レポートの作成に貢献したシニアマネージャー、製品ポートフォリオマネージャー、CEO、副社長、マーケティング/プロダクトマネージャー、マーケットインテリジェンスマネージャーにインタビューを行った。

一次および二次リソースから取得した包括的な情報は、市場に参入している企業からの検証として機能し、膀胱癌治療薬市場の成長見通しに関するPersistence Market Researchの予測をより正確で信頼性の高いものにします。

ページTOPに戻る


目次

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

4. Key Success Factors

    4.1. Product Adoption Analysis

    4.2. Key Strategies, by Manufacturers

    4.3. Regulatory Scenario

    4.4. Porters Analysis

    4.5. PESTLE Analysis

    4.6. Supply Chain Analysis

    4.7. Funding In Research & Development

    4.8. Clinical Trials Analysis

    4.9. Pipeline Analysis

    4.10. Disease Epidemiology, by Region

    4.11. Reimbursement Scenario

    4.12. Parent Market Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Pharmaceutical Industry Overview

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Rising Healthcare Spending

        5.2.2. Increasing Prevalence of Cancer

        5.2.3. Increasing Awareness and Supportive Government Initiatives

        5.2.4. Increase in Funding for

        5.2.5. Cancer Research

        5.2.6. Increase In Product Launches

        5.2.7. Strong Product Pipeline

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

        6.1.1. Impact of COVID-19 - 2021 Market Scenario

        6.1.2. COVID-19 Impact Summary

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012-2022 and Forecast, 2023-2033

    7.1. Historical Market Value (US$ Mn) Analysis, 2012-2022

    7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Bladder Cancer Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis by Bladder Cancer Type, 2012-2022

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Bladder Cancer Type, 2023-2033

        8.3.1. Non-Muscle-Invasive Bladder Cancer

        8.3.2. Muscle-Invasive Bladder Cancer

    8.4. Market Attractiveness Analysis by Bladder Cancer Type

9. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Cancer grade

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis by Cancer grade, 2012-2022

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Cancer grade, 2023-2033

        9.3.1. Low-grade bladder cancer

        9.3.2. High-grade bladder cancer

    9.4. Market Attractiveness Analysis by Cancer grade

10. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Drug Type

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis by Drug Type, 2012-2022

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Drug Type, 2023-2033

        10.3.1. Immunotherapy

            10.3.1.1. Bacillus Calmette-Guerin

            10.3.1.2. Avelumab

            10.3.1.3. Nivolumab

            10.3.1.4. Pembrolizumab

            10.3.1.5. Others

        10.3.2. Chemotherapy

            10.3.2.1. Mitomycin C

            10.3.2.2. Docetaxel

            10.3.2.3. Paclitaxel

            10.3.2.4. Cisplatin

            10.3.2.5. Others

        10.3.3. Targeted therapy

            10.3.3.1. Erdafitinib

            10.3.3.2. Enfortumab vedotin-ejfv

            10.3.3.3. Sacituzumab govitecan

            10.3.3.4. Others

    10.4. Market Attractiveness Analysis by Drug Type

11. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2022

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033

        11.3.1. Hospital Pharmacy

        11.3.2. Retail Pharmacy

        11.3.3. Specialty Pharmacy

        11.3.4. Online Pharmacy

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2022

    12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia

        12.3.6. Oceania

        12.3.7. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2012-2022 and Forecast 2023-2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022

    13.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy 2023-2033

        13.3.1. By Country

            13.3.1.1. U.S.

            13.3.1.2. Canada

        13.3.2. By Bladder Cancer Type

        13.3.3. By Cancer Grade

        13.3.4. By Drug Type

        13.3.5. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Bladder Cancer Type

        13.4.3. By Cancer Grade

        13.4.4. By Drug Type

        13.4.5. By Distribution Channel

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

    13.7. Country-Level Analysis & Forecast

        13.7.1. U.S. Market Analysis

            13.7.1.1. .Introduction

            13.7.1.2. Market Analysis and Forecast by Market Taxonomy

                13.7.1.2.1. By Bladder Cancer Type

                13.7.1.2.2. By Cancer Grade

                13.7.1.2.3. By Drug Type

                13.7.1.2.4. By Distribution Channel

        13.7.2. Canada Market Analysis

            13.7.2.1. Introduction

            13.7.2.2. Market Analysis and Forecast by Market Taxonomy

                13.7.2.2.1. By Bladder Cancer Type

                13.7.2.2.2. By Cancer Grade

                13.7.2.2.3. By Drug Type

                13.7.2.2.4. By Distribution Channel

14. Latin America Market Analysis 2012-2022 and Forecast 2023-2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    14.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        14.3.1. By Country

            14.3.1.1. Mexico

            14.3.1.2. Brazil

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin America

        14.3.2. By Bladder Cancer Type

        14.3.3. By Cancer Grade

        14.3.4. By Drug Type

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Bladder Cancer Type

        14.4.3. By Cancer Grade

        14.4.4. By Drug Type

        14.4.5. By Distribution Channel

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

    14.7. Country-Level Analysis & Forecast

        14.7.1. Mexico Market Analysis

            14.7.1.1. Introduction

            14.7.1.2. Market Analysis and Forecast by Market Taxonomy

                14.7.1.2.1. By Bladder Cancer Type

                14.7.1.2.2. By Cancer Grade

                14.7.1.2.3. By Drug Type

                14.7.1.2.4. By Distribution Channel

        14.7.2. Brazil Market Analysis

            14.7.2.1. Introduction

            14.7.2.2. Market Analysis and Forecast by Market Taxonomy

                14.7.2.2.1. By Bladder Cancer Type

                14.7.2.2.2. By Cancer Grade

                14.7.2.2.3. By Drug Type

                14.7.2.2.4. By Distribution Channel

        14.7.3. Argentina Market Analysis

            14.7.3.1. Introduction

            14.7.3.2. Market Analysis and Forecast by Market Taxonomy

                14.7.3.2.1. By Bladder Cancer Type

                14.7.3.2.2. By Cancer Grade

                14.7.3.2.3. By Drug Type

                14.7.3.2.4. By Distribution Channel

15. Europe Market Analysis 2012-2022 and Forecast 2023-2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022

    15.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        15.3.1. By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. U.K.

            15.3.1.5. Spain

            15.3.1.6. Poland

            15.3.1.7. Russia

            15.3.1.8. Rest of Europe

        15.3.2. By Bladder Cancer Type

        15.3.3. By Cancer Grade

        15.3.4. By Drug Type

        15.3.5. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Bladder Cancer Type

        15.4.3. By Cancer Grade

        15.4.4. By Drug Type

        15.4.5. By Distribution Channel

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

    15.7. Country-Level Analysis & Forecast

        15.7.1. Germany Market Analysis

            15.7.1.1. Introduction

            15.7.1.2. Market Analysis and Forecast by Market Taxonomy

                15.7.1.2.1. By Bladder Cancer Type

                15.7.1.2.2. By Cancer Grade

                15.7.1.2.3. By Drug Type

                15.7.1.2.4. By Distribution Channel

        15.7.2. Italy Market Analysis

            15.7.2.1. Introduction

            15.7.2.2. Market Analysis and Forecast by Market Taxonomy

                15.7.2.2.1. By Bladder Cancer Type

                15.7.2.2.2. By Cancer Grade

                15.7.2.2.3. By Drug Type

                15.7.2.2.4. By Distribution Channel

        15.7.3. France Market Analysis

            15.7.3.1. Introduction

            15.7.3.2. Market Analysis and Forecast by Market Taxonomy

                15.7.3.2.1. By Bladder Cancer Type

                15.7.3.2.2. By Cancer Grade

                15.7.3.2.3. By Drug Type

                15.7.3.2.4. By Distribution Channel

        15.7.4. U.K. Market Analysis

            15.7.4.1. Introduction

            15.7.4.2. Market Analysis and Forecast by Market Taxonomy

                15.7.4.2.1. By Bladder Cancer Type

                15.7.4.2.2. By Cancer Grade

                15.7.4.2.3. By Drug Type

                15.7.4.2.4. By Distribution Channel

        15.7.5. Spain Market Analysis

            15.7.5.1. Introduction

            15.7.5.2. Market Analysis and Forecast by Market Taxonomy

                15.7.5.2.1. By Bladder Cancer Type

                15.7.5.2.2. By Cancer Grade

                15.7.5.2.3. By Drug Type

                15.7.5.2.4. By Distribution Channel

        15.7.6. Poland Market Analysis

            15.7.6.1. Introduction

            15.7.6.2. Market Analysis and Forecast by Market Taxonomy

                15.7.6.2.1. By Bladder Cancer Type

                15.7.6.2.2. By Cancer Grade

                15.7.6.2.3. By Drug Type

                15.7.6.2.4. By Distribution Channel

        15.7.7. Russia Market Analysis

            15.7.7.1. Introduction

            15.7.7.2. Market Analysis and Forecast by Market Taxonomy

                15.7.7.2.1. By Bladder Cancer Type

                15.7.7.2.2. By Cancer Grade

                15.7.7.2.3. By Drug Type

                15.7.7.2.4. By Distribution Channel

16. South Asia Market Analysis 2012-2022 and Forecast 2023-2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    16.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        16.3.1. By Country

            16.3.1.1. India

            16.3.1.2. Indonesia

            16.3.1.3. Malaysia

            16.3.1.4. Thailand

            16.3.1.5. Rest of South Asia

        16.3.2. By Bladder Cancer Type

        16.3.3. By Cancer Grade

        16.3.4. By Drug Type

        16.3.5. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Bladder Cancer Type

        16.4.3. By Cancer Grade

        16.4.4. By Drug Type

        16.4.5. By Distribution Channel

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

    16.7. Country-Level Analysis & Forecast

        16.7.1. India Market Analysis

            16.7.1.1. Introduction

            16.7.1.2. Market Analysis and Forecast by Market Taxonomy

                16.7.1.2.1. By Bladder Cancer Type

                16.7.1.2.2. By Cancer Grade

                16.7.1.2.3. By Drug Type

                16.7.1.2.4. By Distribution Channel

        16.7.2. Indonesia Market Analysis

            16.7.2.1. Introduction

            16.7.2.2. Market Analysis and Forecast by Market Taxonomy

                16.7.2.2.1. By Bladder Cancer Type

                16.7.2.2.2. By Cancer Grade

                16.7.2.2.3. By Drug Type

                16.7.2.2.4. By Distribution Channel

        16.7.3. Malaysia Market Analysis

            16.7.3.1. Introduction

            16.7.3.2. Market Analysis and Forecast by Market Taxonomy

                16.7.3.2.1. By Bladder Cancer Type

                16.7.3.2.2. By Cancer Grade

                16.7.3.2.3. By Drug Type

                16.7.3.2.4. By Distribution Channel

        16.7.4. Thailand Market Analysis

            16.7.4.1. Introduction

            16.7.4.2. Market Analysis and Forecast by Market Taxonomy

                16.7.4.2.1. By Bladder Cancer Type

                16.7.4.2.2. By Cancer Grade

                16.7.4.2.3. By Drug Type

                16.7.4.2.4. By Distribution Channel

17. East Asia Market Analysis 2012-2022 and Forecast 2023-2033

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    17.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        17.3.1. By Country

            17.3.1.1. China

            17.3.1.2. Japan

            17.3.1.3. South Korea

        17.3.2. By Bladder Cancer Type

        17.3.3. By Cancer Grade

        17.3.4. By Drug Type

        17.3.5. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Bladder Cancer Type

        17.4.3. By Cancer Grade

        17.4.4. By Drug Type

        17.4.5. By Distribution Channel

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

    17.7. Country-Level Analysis & Forecast

        17.7.1. China Market Analysis

            17.7.1.1. Introduction

            17.7.1.2. Market Analysis and Forecast by Market Taxonomy

                17.7.1.2.1. By Bladder Cancer Type

                17.7.1.2.2. By Cancer Grade

                17.7.1.2.3. By Drug Type

                17.7.1.2.4. By Distribution Channel

        17.7.2. Japan Market Analysis

            17.7.2.1. Introduction

            17.7.2.2. Market Analysis and Forecast by Market Taxonomy

                17.7.2.2.1. By Bladder Cancer Type

                17.7.2.2.2. By Cancer Grade

                17.7.2.2.3. By Drug Type

                17.7.2.2.4. By Distribution Channel

        17.7.3. South Korea Drugs Market Analysis

            17.7.3.1. Introduction

            17.7.3.2. Market Analysis and Forecast by Market Taxonomy

                17.7.3.2.1. By Bladder Cancer Type

                17.7.3.2.2. By Cancer Grade

                17.7.3.2.3. By Drug Type

                17.7.3.2.4. By Distribution Channel

18. Oceania Market 2012-2022 and Forecast 2022-2033

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2022

    18.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        18.3.1. By Country

            18.3.1.1. Australia

            18.3.1.2. New Zealand

        18.3.2. By Bladder Cancer Type

        18.3.3. By Cancer Grade

        18.3.4. By Drug Type

        18.3.5. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Bladder Cancer Type

        18.4.3. By Cancer Grade

        18.4.4. By Drug Type

        18.4.5. By Distribution Channel

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

    18.7. Country-Level Analysis & Forecast

        18.7.1. Australia Market Analysis

            18.7.1.1. Introduction

            18.7.1.2. Market Analysis and Forecast by Market Taxonomy

                18.7.1.2.1. By Bladder Cancer Type

                18.7.1.2.2. By Cancer Grade

                18.7.1.2.3. By Drug Type

                18.7.1.2.4. By Distribution Channel

        18.7.2. New Zealand Market Analysis

            18.7.2.1. Introduction

            18.7.2.2. Market Analysis and Forecast by Market Taxonomy

                18.7.2.2.1. By Bladder Cancer Type

                18.7.2.2.2. By Cancer Grade

                18.7.2.2.3. By Drug Type

                18.7.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Market Analysis 2012-2022 and Forecast 2023-2033

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    19.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        19.3.1. By Country

            19.3.1.1. GCC Countries

            19.3.1.2. South Africa

            19.3.1.3. North Africa

            19.3.1.4. Türkiye

            19.3.1.5. Rest of Middle East and Africa

        19.3.2. By Bladder Cancer Type

        19.3.3. By Cancer Grade

        19.3.4. By Drug Type

        19.3.5. By Distribution Channel

    19.4. Market Attractiveness Analysis

        19.4.1. By Country

        19.4.2. By Bladder Cancer Type

        19.4.3. By Cancer Grade

        19.4.4. By Drug Type

        19.4.5. By Distribution Channel

    19.5. Key Market Participants - Intensity Mapping

    19.6. Drivers and Restraints - Impact Analysis

    19.7. Country-Level Analysis & Forecast

        19.7.1. GCC Countries Market Analysis

            19.7.1.1. Introduction

            19.7.1.2. Market Analysis and Forecast by Market Taxonomy

                19.7.1.2.1. By Bladder Cancer Type

                19.7.1.2.2. By Cancer Grade

                19.7.1.2.3. By Drug Type

                19.7.1.2.4. By Distribution Channel

        19.7.2. South Africa Market Analysis

            19.7.2.1. Introduction

            19.7.2.2. Market Analysis and Forecast by Market Taxonomy

                19.7.2.2.1. By Bladder Cancer Type

                19.7.2.2.2. By Cancer Grade

                19.7.2.2.3. By Drug Type

                19.7.2.2.4. By Distribution Channel

        19.7.3. North Africa Market Analysis

            19.7.3.1. Introduction

            19.7.3.2. Market Analysis and Forecast by Market Taxonomy

                19.7.3.2.1. By Bladder Cancer Type

                19.7.3.2.2. By Cancer Grade

                19.7.3.2.3. By Drug Type

                19.7.3.2.4. By Distribution Channel

        19.7.4. Türkiye Market Analysis

            19.7.4.1. Introduction

            19.7.4.2. Market Analysis and Forecast by Market Taxonomy

                19.7.4.2.1. By Bladder Cancer Type

                19.7.4.2.2. By Cancer Grade

                19.7.4.2.3. By Drug Type

                19.7.4.2.4. By Distribution Channel

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies

    20.2. Market Share Analysis of Top Players

    20.3. Market Presence Analysis

        20.3.1. By Regional footprint of Players

        20.3.2. Product footprint by Players

        20.3.3. Channel Foot Print by Players

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive [Tentative list]

        21.3.1. Pfizer Inc.

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Business Segment Overview

            21.3.1.4. Sales Footprint

            21.3.1.5. SWOT Analysis

            21.3.1.6. Key Financials

            21.3.1.7. Strategy Overview

        21.3.2. Merck KGaA

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Business Segment Overview

            21.3.2.4. Sales Footprint

            21.3.2.5. SWOT Analysis

            21.3.2.6. Key Financials

            21.3.2.7. Strategy Overview

        21.3.3. Merck & Co

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Business Segment Overview

            21.3.3.4. Sales Footprint

            21.3.3.5. SWOT Analysis

            21.3.3.6. Key Financials

            21.3.3.7. Strategy Overview

        21.3.4. AstraZeneca PLC

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Business Segment Overview

            21.3.4.4. Sales Footprint

            21.3.4.5. SWOT Analysis

            21.3.4.6. Key Financials

            21.3.4.7. Strategy Overview

        21.3.5. Roche Holding AG (Genentech)

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Business Segment Overview

            21.3.5.4. Sales Footprint

            21.3.5.5. SWOT Analysis

            21.3.5.6. Key Financials

            21.3.5.7. Strategy Overview

        21.3.6. Astellas Pharma Inc.

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Business Segment Overview

            21.3.6.4. Sales Footprint

            21.3.6.5. SWOT Analysis

            21.3.6.6. Key Financials

            21.3.6.7. Strategy Overview

        21.3.7. J&J (Janssen Biotech)

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Business Segment Overview

            21.3.7.4. Sales Footprint

            21.3.7.5. SWOT Analysis

            21.3.7.6. Key Financials

            21.3.7.7. Strategy Overview

        21.3.8. Cipla Inc.

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Business Segment Overview

            21.3.8.4. Sales Footprint

            21.3.8.5. SWOT Analysis

            21.3.8.6. Key Financials

            21.3.8.7. Strategy Overview

        21.3.9. Amneal Pharma

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Business Segment Overview

            21.3.9.4. Sales Footprint

            21.3.9.5. SWOT Analysis

            21.3.9.6. Key Financials

            21.3.9.7. Strategy Overview

        21.3.10. Bristol Myers Squibb Co.

            21.3.10.1. Overview

            21.3.10.2. Product Portfolio

            21.3.10.3. Business Segment Overview

            21.3.10.4. Sales Footprint

            21.3.10.5. SWOT Analysis

            21.3.10.6. Key Financials

            21.3.10.7. Strategy Overview

        21.3.11. Dr. Reddy’s Laboratories, Inc.

            21.3.11.1. Overview

            21.3.11.2. Product Portfolio

            21.3.11.3. Business Segment Overview

            21.3.11.4. Sales Footprint

            21.3.11.5. SWOT Analysis

            21.3.11.6. Key Financials

            21.3.11.7. Strategy Overview

        21.3.12. Gilead Sciences Inc.

            21.3.12.1. Overview

            21.3.12.2. Product Portfolio

            21.3.12.3. Business Segment Overview

            21.3.12.4. Sales Footprint

            21.3.12.5. SWOT Analysis

            21.3.12.6. Key Financials

            21.3.12.7. Strategy Overview

        21.3.13. Endo Pharma

            21.3.13.1. Overview

            21.3.13.2. Product Portfolio

            21.3.13.3. Business Segment Overview

            21.3.13.4. Sales Footprint

            21.3.13.5. SWOT Analysis

            21.3.13.6. Key Financials

            21.3.13.7. Strategy Overview

        21.3.14. UroGen Pharma, Inc.

            21.3.14.1. Overview

            21.3.14.2. Product Portfolio

            21.3.14.3. Business Segment Overview

            21.3.14.4. Sales Footprint

            21.3.14.5. SWOT Analysis

            21.3.14.6. Key Financials

            21.3.14.7. Strategy Overview

        21.3.15. Teva Pharmaceuticals (Actavis)

            21.3.15.1. Overview

            21.3.15.2. Product Portfolio

            21.3.15.3. Business Segment Overview

            21.3.15.4. Sales Footprint

            21.3.15.5. SWOT Analysis

            21.3.15.6. Key Financials

            21.3.15.7. Strategy Overview

        21.3.16. Hikma Pharmaceuticals

            21.3.16.1. Overview

            21.3.16.2. Product Portfolio

            21.3.16.3. Business Segment Overview

            21.3.16.4. Sales Footprint

            21.3.16.5. SWOT Analysis

            21.3.16.6. Key Financials

            21.3.16.7. Strategy Overview

        21.3.17. Incyte

            21.3.17.1. Overview

            21.3.17.2. Product Portfolio

            21.3.17.3. Business Segment Overview

            21.3.17.4. Sales Footprint

            21.3.17.5. SWOT Analysis

            21.3.17.6. Key Financials

            21.3.17.7. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology

ページTOPに戻る



図表リスト

Table 01: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 02: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 03: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 04: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 05: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 06: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 07: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 08: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 09: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Region

Table 10: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Region

Table 11: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 12: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 13: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 14: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 15: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 16: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 17: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 18: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 19: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 20: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 21: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 22: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 23: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 24: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 25: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 26: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 27: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 28: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 29: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 30: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 31: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 32: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 33: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 34: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 35: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 36: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 37: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 38: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 39: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 40: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 41: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 42: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 43: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 44: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 45: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 46: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 47: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 48: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 49: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 50: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 51: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 52: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 53: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 54: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 55: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 56: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 57: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 58: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 59: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 60: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 61: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 62: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 63: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 64: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 65: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 66: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 67: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 68: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 69: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 70: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 71: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 72: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 73: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 74: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 75: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 76: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 77: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 78: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 79: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 80: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

 

ページTOPに戻る


 

Summary

Bladder Cancer Treatment Drugs Market – Report Scope

The latest publication by Persistence Market Research on the global bladder cancer treatment drugs market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2023 to 2033.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for bladder cancer treatment drugs and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the bladder cancer treatment drugs market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the bladder cancer treatment drugs market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as macroeconomic variables affecting the business scenario in the bladder cancer treatment drugs market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research’s study on the bladder cancer treatment drugs market offers information divided into five important segments – cancer type, cancer grade, drug type, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Cancer Type

Non-Muscle-Invasive Bladder Cancer
Muscle-Invasive Bladder Cancer
Cancer Grade

Low-Grade Bladder Cancer
High-Grade Bladder Cancer
Drug Type

Immunotherapy
Bacillus Calmette-Guerin
Avelumab
Nivolumab
Pembrolizumab
Others
Chemotherapy
Mitomycin C
Docetaxel
Paclitaxel
Cisplatin
Others
Targeted Therapy
Erdafitinib
Enfortumab vedotin-ejfv
Sacituzumab govitecan
Others
Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Online Pharmacies
Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Questions Answered in Study

Which regions will continue to remain the most profitable markets for bladder cancer treatment drug manufacturers over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the bladder cancer treatment drugs market avail themselves of the growth opportunities in developed and emerging sectors?
Research Methodology

In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the bladder cancer treatment drugs market and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the bladder cancer treatment drugs market more accurate and reliable.



ページTOPに戻る


Table of Contents

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

4. Key Success Factors

    4.1. Product Adoption Analysis

    4.2. Key Strategies, by Manufacturers

    4.3. Regulatory Scenario

    4.4. Porters Analysis

    4.5. PESTLE Analysis

    4.6. Supply Chain Analysis

    4.7. Funding In Research & Development

    4.8. Clinical Trials Analysis

    4.9. Pipeline Analysis

    4.10. Disease Epidemiology, by Region

    4.11. Reimbursement Scenario

    4.12. Parent Market Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Pharmaceutical Industry Overview

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Rising Healthcare Spending

        5.2.2. Increasing Prevalence of Cancer

        5.2.3. Increasing Awareness and Supportive Government Initiatives

        5.2.4. Increase in Funding for

        5.2.5. Cancer Research

        5.2.6. Increase In Product Launches

        5.2.7. Strong Product Pipeline

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

        6.1.1. Impact of COVID-19 - 2021 Market Scenario

        6.1.2. COVID-19 Impact Summary

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012-2022 and Forecast, 2023-2033

    7.1. Historical Market Value (US$ Mn) Analysis, 2012-2022

    7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Bladder Cancer Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis by Bladder Cancer Type, 2012-2022

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Bladder Cancer Type, 2023-2033

        8.3.1. Non-Muscle-Invasive Bladder Cancer

        8.3.2. Muscle-Invasive Bladder Cancer

    8.4. Market Attractiveness Analysis by Bladder Cancer Type

9. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Cancer grade

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis by Cancer grade, 2012-2022

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Cancer grade, 2023-2033

        9.3.1. Low-grade bladder cancer

        9.3.2. High-grade bladder cancer

    9.4. Market Attractiveness Analysis by Cancer grade

10. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Drug Type

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis by Drug Type, 2012-2022

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Drug Type, 2023-2033

        10.3.1. Immunotherapy

            10.3.1.1. Bacillus Calmette-Guerin

            10.3.1.2. Avelumab

            10.3.1.3. Nivolumab

            10.3.1.4. Pembrolizumab

            10.3.1.5. Others

        10.3.2. Chemotherapy

            10.3.2.1. Mitomycin C

            10.3.2.2. Docetaxel

            10.3.2.3. Paclitaxel

            10.3.2.4. Cisplatin

            10.3.2.5. Others

        10.3.3. Targeted therapy

            10.3.3.1. Erdafitinib

            10.3.3.2. Enfortumab vedotin-ejfv

            10.3.3.3. Sacituzumab govitecan

            10.3.3.4. Others

    10.4. Market Attractiveness Analysis by Drug Type

11. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2022

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033

        11.3.1. Hospital Pharmacy

        11.3.2. Retail Pharmacy

        11.3.3. Specialty Pharmacy

        11.3.4. Online Pharmacy

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2022

    12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia

        12.3.6. Oceania

        12.3.7. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2012-2022 and Forecast 2023-2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022

    13.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy 2023-2033

        13.3.1. By Country

            13.3.1.1. U.S.

            13.3.1.2. Canada

        13.3.2. By Bladder Cancer Type

        13.3.3. By Cancer Grade

        13.3.4. By Drug Type

        13.3.5. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Bladder Cancer Type

        13.4.3. By Cancer Grade

        13.4.4. By Drug Type

        13.4.5. By Distribution Channel

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

    13.7. Country-Level Analysis & Forecast

        13.7.1. U.S. Market Analysis

            13.7.1.1. .Introduction

            13.7.1.2. Market Analysis and Forecast by Market Taxonomy

                13.7.1.2.1. By Bladder Cancer Type

                13.7.1.2.2. By Cancer Grade

                13.7.1.2.3. By Drug Type

                13.7.1.2.4. By Distribution Channel

        13.7.2. Canada Market Analysis

            13.7.2.1. Introduction

            13.7.2.2. Market Analysis and Forecast by Market Taxonomy

                13.7.2.2.1. By Bladder Cancer Type

                13.7.2.2.2. By Cancer Grade

                13.7.2.2.3. By Drug Type

                13.7.2.2.4. By Distribution Channel

14. Latin America Market Analysis 2012-2022 and Forecast 2023-2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    14.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        14.3.1. By Country

            14.3.1.1. Mexico

            14.3.1.2. Brazil

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin America

        14.3.2. By Bladder Cancer Type

        14.3.3. By Cancer Grade

        14.3.4. By Drug Type

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Bladder Cancer Type

        14.4.3. By Cancer Grade

        14.4.4. By Drug Type

        14.4.5. By Distribution Channel

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

    14.7. Country-Level Analysis & Forecast

        14.7.1. Mexico Market Analysis

            14.7.1.1. Introduction

            14.7.1.2. Market Analysis and Forecast by Market Taxonomy

                14.7.1.2.1. By Bladder Cancer Type

                14.7.1.2.2. By Cancer Grade

                14.7.1.2.3. By Drug Type

                14.7.1.2.4. By Distribution Channel

        14.7.2. Brazil Market Analysis

            14.7.2.1. Introduction

            14.7.2.2. Market Analysis and Forecast by Market Taxonomy

                14.7.2.2.1. By Bladder Cancer Type

                14.7.2.2.2. By Cancer Grade

                14.7.2.2.3. By Drug Type

                14.7.2.2.4. By Distribution Channel

        14.7.3. Argentina Market Analysis

            14.7.3.1. Introduction

            14.7.3.2. Market Analysis and Forecast by Market Taxonomy

                14.7.3.2.1. By Bladder Cancer Type

                14.7.3.2.2. By Cancer Grade

                14.7.3.2.3. By Drug Type

                14.7.3.2.4. By Distribution Channel

15. Europe Market Analysis 2012-2022 and Forecast 2023-2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022

    15.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        15.3.1. By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. U.K.

            15.3.1.5. Spain

            15.3.1.6. Poland

            15.3.1.7. Russia

            15.3.1.8. Rest of Europe

        15.3.2. By Bladder Cancer Type

        15.3.3. By Cancer Grade

        15.3.4. By Drug Type

        15.3.5. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Bladder Cancer Type

        15.4.3. By Cancer Grade

        15.4.4. By Drug Type

        15.4.5. By Distribution Channel

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

    15.7. Country-Level Analysis & Forecast

        15.7.1. Germany Market Analysis

            15.7.1.1. Introduction

            15.7.1.2. Market Analysis and Forecast by Market Taxonomy

                15.7.1.2.1. By Bladder Cancer Type

                15.7.1.2.2. By Cancer Grade

                15.7.1.2.3. By Drug Type

                15.7.1.2.4. By Distribution Channel

        15.7.2. Italy Market Analysis

            15.7.2.1. Introduction

            15.7.2.2. Market Analysis and Forecast by Market Taxonomy

                15.7.2.2.1. By Bladder Cancer Type

                15.7.2.2.2. By Cancer Grade

                15.7.2.2.3. By Drug Type

                15.7.2.2.4. By Distribution Channel

        15.7.3. France Market Analysis

            15.7.3.1. Introduction

            15.7.3.2. Market Analysis and Forecast by Market Taxonomy

                15.7.3.2.1. By Bladder Cancer Type

                15.7.3.2.2. By Cancer Grade

                15.7.3.2.3. By Drug Type

                15.7.3.2.4. By Distribution Channel

        15.7.4. U.K. Market Analysis

            15.7.4.1. Introduction

            15.7.4.2. Market Analysis and Forecast by Market Taxonomy

                15.7.4.2.1. By Bladder Cancer Type

                15.7.4.2.2. By Cancer Grade

                15.7.4.2.3. By Drug Type

                15.7.4.2.4. By Distribution Channel

        15.7.5. Spain Market Analysis

            15.7.5.1. Introduction

            15.7.5.2. Market Analysis and Forecast by Market Taxonomy

                15.7.5.2.1. By Bladder Cancer Type

                15.7.5.2.2. By Cancer Grade

                15.7.5.2.3. By Drug Type

                15.7.5.2.4. By Distribution Channel

        15.7.6. Poland Market Analysis

            15.7.6.1. Introduction

            15.7.6.2. Market Analysis and Forecast by Market Taxonomy

                15.7.6.2.1. By Bladder Cancer Type

                15.7.6.2.2. By Cancer Grade

                15.7.6.2.3. By Drug Type

                15.7.6.2.4. By Distribution Channel

        15.7.7. Russia Market Analysis

            15.7.7.1. Introduction

            15.7.7.2. Market Analysis and Forecast by Market Taxonomy

                15.7.7.2.1. By Bladder Cancer Type

                15.7.7.2.2. By Cancer Grade

                15.7.7.2.3. By Drug Type

                15.7.7.2.4. By Distribution Channel

16. South Asia Market Analysis 2012-2022 and Forecast 2023-2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    16.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        16.3.1. By Country

            16.3.1.1. India

            16.3.1.2. Indonesia

            16.3.1.3. Malaysia

            16.3.1.4. Thailand

            16.3.1.5. Rest of South Asia

        16.3.2. By Bladder Cancer Type

        16.3.3. By Cancer Grade

        16.3.4. By Drug Type

        16.3.5. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Bladder Cancer Type

        16.4.3. By Cancer Grade

        16.4.4. By Drug Type

        16.4.5. By Distribution Channel

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

    16.7. Country-Level Analysis & Forecast

        16.7.1. India Market Analysis

            16.7.1.1. Introduction

            16.7.1.2. Market Analysis and Forecast by Market Taxonomy

                16.7.1.2.1. By Bladder Cancer Type

                16.7.1.2.2. By Cancer Grade

                16.7.1.2.3. By Drug Type

                16.7.1.2.4. By Distribution Channel

        16.7.2. Indonesia Market Analysis

            16.7.2.1. Introduction

            16.7.2.2. Market Analysis and Forecast by Market Taxonomy

                16.7.2.2.1. By Bladder Cancer Type

                16.7.2.2.2. By Cancer Grade

                16.7.2.2.3. By Drug Type

                16.7.2.2.4. By Distribution Channel

        16.7.3. Malaysia Market Analysis

            16.7.3.1. Introduction

            16.7.3.2. Market Analysis and Forecast by Market Taxonomy

                16.7.3.2.1. By Bladder Cancer Type

                16.7.3.2.2. By Cancer Grade

                16.7.3.2.3. By Drug Type

                16.7.3.2.4. By Distribution Channel

        16.7.4. Thailand Market Analysis

            16.7.4.1. Introduction

            16.7.4.2. Market Analysis and Forecast by Market Taxonomy

                16.7.4.2.1. By Bladder Cancer Type

                16.7.4.2.2. By Cancer Grade

                16.7.4.2.3. By Drug Type

                16.7.4.2.4. By Distribution Channel

17. East Asia Market Analysis 2012-2022 and Forecast 2023-2033

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    17.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        17.3.1. By Country

            17.3.1.1. China

            17.3.1.2. Japan

            17.3.1.3. South Korea

        17.3.2. By Bladder Cancer Type

        17.3.3. By Cancer Grade

        17.3.4. By Drug Type

        17.3.5. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Bladder Cancer Type

        17.4.3. By Cancer Grade

        17.4.4. By Drug Type

        17.4.5. By Distribution Channel

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

    17.7. Country-Level Analysis & Forecast

        17.7.1. China Market Analysis

            17.7.1.1. Introduction

            17.7.1.2. Market Analysis and Forecast by Market Taxonomy

                17.7.1.2.1. By Bladder Cancer Type

                17.7.1.2.2. By Cancer Grade

                17.7.1.2.3. By Drug Type

                17.7.1.2.4. By Distribution Channel

        17.7.2. Japan Market Analysis

            17.7.2.1. Introduction

            17.7.2.2. Market Analysis and Forecast by Market Taxonomy

                17.7.2.2.1. By Bladder Cancer Type

                17.7.2.2.2. By Cancer Grade

                17.7.2.2.3. By Drug Type

                17.7.2.2.4. By Distribution Channel

        17.7.3. South Korea Drugs Market Analysis

            17.7.3.1. Introduction

            17.7.3.2. Market Analysis and Forecast by Market Taxonomy

                17.7.3.2.1. By Bladder Cancer Type

                17.7.3.2.2. By Cancer Grade

                17.7.3.2.3. By Drug Type

                17.7.3.2.4. By Distribution Channel

18. Oceania Market 2012-2022 and Forecast 2022-2033

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2022

    18.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        18.3.1. By Country

            18.3.1.1. Australia

            18.3.1.2. New Zealand

        18.3.2. By Bladder Cancer Type

        18.3.3. By Cancer Grade

        18.3.4. By Drug Type

        18.3.5. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Bladder Cancer Type

        18.4.3. By Cancer Grade

        18.4.4. By Drug Type

        18.4.5. By Distribution Channel

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

    18.7. Country-Level Analysis & Forecast

        18.7.1. Australia Market Analysis

            18.7.1.1. Introduction

            18.7.1.2. Market Analysis and Forecast by Market Taxonomy

                18.7.1.2.1. By Bladder Cancer Type

                18.7.1.2.2. By Cancer Grade

                18.7.1.2.3. By Drug Type

                18.7.1.2.4. By Distribution Channel

        18.7.2. New Zealand Market Analysis

            18.7.2.1. Introduction

            18.7.2.2. Market Analysis and Forecast by Market Taxonomy

                18.7.2.2.1. By Bladder Cancer Type

                18.7.2.2.2. By Cancer Grade

                18.7.2.2.3. By Drug Type

                18.7.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Market Analysis 2012-2022 and Forecast 2023-2033

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    19.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        19.3.1. By Country

            19.3.1.1. GCC Countries

            19.3.1.2. South Africa

            19.3.1.3. North Africa

            19.3.1.4. Türkiye

            19.3.1.5. Rest of Middle East and Africa

        19.3.2. By Bladder Cancer Type

        19.3.3. By Cancer Grade

        19.3.4. By Drug Type

        19.3.5. By Distribution Channel

    19.4. Market Attractiveness Analysis

        19.4.1. By Country

        19.4.2. By Bladder Cancer Type

        19.4.3. By Cancer Grade

        19.4.4. By Drug Type

        19.4.5. By Distribution Channel

    19.5. Key Market Participants - Intensity Mapping

    19.6. Drivers and Restraints - Impact Analysis

    19.7. Country-Level Analysis & Forecast

        19.7.1. GCC Countries Market Analysis

            19.7.1.1. Introduction

            19.7.1.2. Market Analysis and Forecast by Market Taxonomy

                19.7.1.2.1. By Bladder Cancer Type

                19.7.1.2.2. By Cancer Grade

                19.7.1.2.3. By Drug Type

                19.7.1.2.4. By Distribution Channel

        19.7.2. South Africa Market Analysis

            19.7.2.1. Introduction

            19.7.2.2. Market Analysis and Forecast by Market Taxonomy

                19.7.2.2.1. By Bladder Cancer Type

                19.7.2.2.2. By Cancer Grade

                19.7.2.2.3. By Drug Type

                19.7.2.2.4. By Distribution Channel

        19.7.3. North Africa Market Analysis

            19.7.3.1. Introduction

            19.7.3.2. Market Analysis and Forecast by Market Taxonomy

                19.7.3.2.1. By Bladder Cancer Type

                19.7.3.2.2. By Cancer Grade

                19.7.3.2.3. By Drug Type

                19.7.3.2.4. By Distribution Channel

        19.7.4. Türkiye Market Analysis

            19.7.4.1. Introduction

            19.7.4.2. Market Analysis and Forecast by Market Taxonomy

                19.7.4.2.1. By Bladder Cancer Type

                19.7.4.2.2. By Cancer Grade

                19.7.4.2.3. By Drug Type

                19.7.4.2.4. By Distribution Channel

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies

    20.2. Market Share Analysis of Top Players

    20.3. Market Presence Analysis

        20.3.1. By Regional footprint of Players

        20.3.2. Product footprint by Players

        20.3.3. Channel Foot Print by Players

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive [Tentative list]

        21.3.1. Pfizer Inc.

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Business Segment Overview

            21.3.1.4. Sales Footprint

            21.3.1.5. SWOT Analysis

            21.3.1.6. Key Financials

            21.3.1.7. Strategy Overview

        21.3.2. Merck KGaA

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Business Segment Overview

            21.3.2.4. Sales Footprint

            21.3.2.5. SWOT Analysis

            21.3.2.6. Key Financials

            21.3.2.7. Strategy Overview

        21.3.3. Merck & Co

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Business Segment Overview

            21.3.3.4. Sales Footprint

            21.3.3.5. SWOT Analysis

            21.3.3.6. Key Financials

            21.3.3.7. Strategy Overview

        21.3.4. AstraZeneca PLC

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Business Segment Overview

            21.3.4.4. Sales Footprint

            21.3.4.5. SWOT Analysis

            21.3.4.6. Key Financials

            21.3.4.7. Strategy Overview

        21.3.5. Roche Holding AG (Genentech)

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Business Segment Overview

            21.3.5.4. Sales Footprint

            21.3.5.5. SWOT Analysis

            21.3.5.6. Key Financials

            21.3.5.7. Strategy Overview

        21.3.6. Astellas Pharma Inc.

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Business Segment Overview

            21.3.6.4. Sales Footprint

            21.3.6.5. SWOT Analysis

            21.3.6.6. Key Financials

            21.3.6.7. Strategy Overview

        21.3.7. J&J (Janssen Biotech)

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Business Segment Overview

            21.3.7.4. Sales Footprint

            21.3.7.5. SWOT Analysis

            21.3.7.6. Key Financials

            21.3.7.7. Strategy Overview

        21.3.8. Cipla Inc.

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Business Segment Overview

            21.3.8.4. Sales Footprint

            21.3.8.5. SWOT Analysis

            21.3.8.6. Key Financials

            21.3.8.7. Strategy Overview

        21.3.9. Amneal Pharma

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Business Segment Overview

            21.3.9.4. Sales Footprint

            21.3.9.5. SWOT Analysis

            21.3.9.6. Key Financials

            21.3.9.7. Strategy Overview

        21.3.10. Bristol Myers Squibb Co.

            21.3.10.1. Overview

            21.3.10.2. Product Portfolio

            21.3.10.3. Business Segment Overview

            21.3.10.4. Sales Footprint

            21.3.10.5. SWOT Analysis

            21.3.10.6. Key Financials

            21.3.10.7. Strategy Overview

        21.3.11. Dr. Reddy’s Laboratories, Inc.

            21.3.11.1. Overview

            21.3.11.2. Product Portfolio

            21.3.11.3. Business Segment Overview

            21.3.11.4. Sales Footprint

            21.3.11.5. SWOT Analysis

            21.3.11.6. Key Financials

            21.3.11.7. Strategy Overview

        21.3.12. Gilead Sciences Inc.

            21.3.12.1. Overview

            21.3.12.2. Product Portfolio

            21.3.12.3. Business Segment Overview

            21.3.12.4. Sales Footprint

            21.3.12.5. SWOT Analysis

            21.3.12.6. Key Financials

            21.3.12.7. Strategy Overview

        21.3.13. Endo Pharma

            21.3.13.1. Overview

            21.3.13.2. Product Portfolio

            21.3.13.3. Business Segment Overview

            21.3.13.4. Sales Footprint

            21.3.13.5. SWOT Analysis

            21.3.13.6. Key Financials

            21.3.13.7. Strategy Overview

        21.3.14. UroGen Pharma, Inc.

            21.3.14.1. Overview

            21.3.14.2. Product Portfolio

            21.3.14.3. Business Segment Overview

            21.3.14.4. Sales Footprint

            21.3.14.5. SWOT Analysis

            21.3.14.6. Key Financials

            21.3.14.7. Strategy Overview

        21.3.15. Teva Pharmaceuticals (Actavis)

            21.3.15.1. Overview

            21.3.15.2. Product Portfolio

            21.3.15.3. Business Segment Overview

            21.3.15.4. Sales Footprint

            21.3.15.5. SWOT Analysis

            21.3.15.6. Key Financials

            21.3.15.7. Strategy Overview

        21.3.16. Hikma Pharmaceuticals

            21.3.16.1. Overview

            21.3.16.2. Product Portfolio

            21.3.16.3. Business Segment Overview

            21.3.16.4. Sales Footprint

            21.3.16.5. SWOT Analysis

            21.3.16.6. Key Financials

            21.3.16.7. Strategy Overview

        21.3.17. Incyte

            21.3.17.1. Overview

            21.3.17.2. Product Portfolio

            21.3.17.3. Business Segment Overview

            21.3.17.4. Sales Footprint

            21.3.17.5. SWOT Analysis

            21.3.17.6. Key Financials

            21.3.17.7. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology

ページTOPに戻る



List of Tables/Graphs

Table 01: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 02: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 03: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 04: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 05: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 06: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 07: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 08: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 09: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Region

Table 10: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Region

Table 11: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 12: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 13: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 14: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 15: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 16: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 17: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 18: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 19: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 20: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 21: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 22: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 23: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 24: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 25: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 26: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 27: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 28: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 29: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 30: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 31: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 32: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 33: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 34: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 35: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 36: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 37: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 38: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 39: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 40: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 41: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 42: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 43: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 44: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 45: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 46: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 47: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 48: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 49: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 50: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 51: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 52: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 53: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 54: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 55: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 56: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 57: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 58: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 59: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 60: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 61: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 62: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 63: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 64: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 65: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 66: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 67: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 68: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 69: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 70: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 71: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 72: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 73: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 74: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 75: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 76: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 77: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 78: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 79: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 80: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療機器)の最新刊レポート

Persistence Market Research社の医療・製薬・メディカルデバイス分野での最新刊レポート


よくあるご質問


Persistence Market Research社はどのような調査会社ですか?


パーシスタンスマーケットリサーチ(Persistence Market Research/PMR)は独自の方法論を用いたデータ解析と市場調査をベースに広範な産業調査報告書とカスタム調査を提供しています... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23 10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る